ReachMD Faculty

Public Profile

Nicholas J. Silvestri, MD
Nicholas J. Silvestri, MD
    Precision Medicine for gMG: Tailoring Treatments Based on Patient Profiles
    Managing Side Effects in FcRn Therapy: Best Practices for gMG
    New Frontiers in MG: How FcRn Antagonists Are Changing MG Therapy
    A Scientific Look at FcRn Antagonists: Mechanisms of Action Explained
    Autoantibodies Explained: Anti-AChR, Anti-MuSK, and Their Diagnostic Role
    Living with gMG: Navigating Personal, Professional, and Mental Health Challenges
    Precision Medicine in Myasthenia Gravis: Crafting Personalized Treatment Strategies
    Optimizing FcRn Therapy: Addressing and Reducing Adverse Reactions
    FcRn Antagonists in Myasthenia Gravis: A New Era in Targeted Therapy
    The Science Behind FcRn Antagonists: A Deep Dive Into Their Mechanism of Action
    Balancing Risk and Benefit: Traditional MG Treatments and Medications to Avoid
    Autoantibodies in MG: Their Role in Diagnosis and Treatment
    Diagnosing gMG: Navigating Current Tools and Approaches
    Life-Threatening Events: Understanding and Preventing Myasthenic Crisis
    Understanding Disease Progression: The Shift From Ocular to Generalized MG
    Beyond the Symptoms: The True Impact of gMG on Patients' Lives
    FcRn Inhibitors: A Potential New Targeted Therapy Option
    Comprehensive CIDP Care: The Role of Multidisciplinary Teams and Patient-Reported Outcomes
    Clinical Benefits of FcRn Inhibitors Clinical Benefits: Innovations in CIDP Management and Treatment
    Novel Mechanisms of Action: FcRn Inhibitors
    Implementing CIDP Clinical Guidelines: Optimizing Therapy
    CIDP Monitoring Challenges: Suboptimal Responses in CIDP Treatment
    Navigating CIDP Treatments: IVIg and Steroid Advantages and Limitations
    Autoantibodies in CIDP: Prevalence and Diagnostic Implications
    Pinpointing CIDP: Diagnosis Challenges and Misdiagnosis/Delayed Diagnosis of CIDP
    Why Early and Accurate CIDP Diagnosis Matters: The Role of Standardized Tools
    Decoding CIDP: Exploring Common and Atypical Variants
    Treatment Advances in Generalized Myasthenia Gravis Addressing the Nuances of its Underlying Immunopathology
    Improving Outcomes Earlier in Generalized Myasthenia Gravis:  Roadmap for Incorporating Targeted Therapies Into Clinical Practice
    Incorporating FcRn Inhibitors Into Clinical Practice in Chronic Inflammatory Demyelinating Polyneuropathy

    Program Chapters

    Segment Chapters

    Playlist:

    Recommended

    Register

    We’re glad to see you’re enjoying ReachMD…
    but how about a more personalized experience?

    Register for free
    PrevNext